OPEN END TURBO BULL OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 20:41:44 31/05/2024 BST | ||
| 8.47 EUR | +16.83% |
|
| 1 month | +165.52% | ||
| 3 months | +31.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 8.47 | +16.83% |
| 30/05/24 | 7.25 | -1.63% |
| 29/05/24 | 7.37 | -4.53% |
| 28/05/24 | 7.72 | -14.51% |
| 27/05/24 | 9.03 | +4.51% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 08:41 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1D7B |
| ISIN | DE000HD1D7B2 |
| Date issued | 22/12/2023 |
| Strike | 364.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.53 € |
|---|---|
| Lowest since issue | 2.71 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
